DK1639010T3 - Terapeutisk surrogatendepunkt for anti-ctla-4-baseret immunterapi af sygdom - Google Patents

Terapeutisk surrogatendepunkt for anti-ctla-4-baseret immunterapi af sygdom Download PDF

Info

Publication number
DK1639010T3
DK1639010T3 DK04785793.3T DK04785793T DK1639010T3 DK 1639010 T3 DK1639010 T3 DK 1639010T3 DK 04785793 T DK04785793 T DK 04785793T DK 1639010 T3 DK1639010 T3 DK 1639010T3
Authority
DK
Denmark
Prior art keywords
immunterapy
ctla
disease
end point
surrogate end
Prior art date
Application number
DK04785793.3T
Other languages
English (en)
Inventor
Israel Lowy
Geoffrey M Nichol
Original Assignee
Squibb & Sons Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Llc filed Critical Squibb & Sons Llc
Application granted granted Critical
Publication of DK1639010T3 publication Critical patent/DK1639010T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK04785793.3T 2003-05-30 2004-05-28 Terapeutisk surrogatendepunkt for anti-ctla-4-baseret immunterapi af sygdom DK1639010T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47506703P 2003-05-30 2003-05-30
PCT/US2004/016995 WO2005003298A2 (en) 2003-05-30 2004-05-28 Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease

Publications (1)

Publication Number Publication Date
DK1639010T3 true DK1639010T3 (da) 2020-09-07

Family

ID=33563738

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04785793.3T DK1639010T3 (da) 2003-05-30 2004-05-28 Terapeutisk surrogatendepunkt for anti-ctla-4-baseret immunterapi af sygdom

Country Status (19)

Country Link
US (2) US7465446B2 (da)
EP (1) EP1639010B1 (da)
JP (1) JP2007502330A (da)
CN (1) CN1816567A (da)
AU (1) AU2004253865B2 (da)
CA (1) CA2527373A1 (da)
CY (1) CY1123535T1 (da)
DK (1) DK1639010T3 (da)
ES (1) ES2813928T3 (da)
HU (1) HUE051533T2 (da)
IL (1) IL172028A (da)
MX (1) MXPA05012832A (da)
NO (1) NO344368B1 (da)
NZ (1) NZ543768A (da)
PL (1) PL1639010T3 (da)
PT (1) PT1639010T (da)
SI (1) SI1639010T1 (da)
WO (1) WO2005003298A2 (da)
ZA (1) ZA200510125B (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) * 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
MXPA04010013A (es) * 2002-04-12 2004-12-13 Medarex Inc Metodos de tratamiento utilizando anticuerpos al antigeno-4 asociado con el linfocito t citotoxico.
ATE481985T1 (de) 2002-07-03 2010-10-15 Ono Pharmaceutical Co Immunpotenzierende zusammensetzungen
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
ES2390278T3 (es) 2004-05-20 2012-11-08 Zymogenetics, Inc. Procedimientos de tratamiento del cáncer usando tratamiento con IL-21 y anticuerpos monoclonales
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
GB0426644D0 (en) * 2004-12-03 2005-01-05 Univ Aberdeen T-cell modulation
EP1896582A4 (en) 2005-05-09 2009-04-08 Ono Pharmaceutical Co HUMAN MONOCLONAL ANTIBODIES FOR PROGRAMMED DEATH 1 (MP-1) AND METHODS FOR TREATING CANCER USING ANTI-MP-1 ANTIBODIES ALONE OR ASSOCIATED WITH OTHER IMMUNOTHERAPIES
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1948214A4 (en) * 2005-11-08 2009-12-30 Medarex Inc ANTI-TNF-ALPHA TREATMENT FOR TREATING ENTEROCOLITIS ASSOCIATED WITH IMMUNOSTIMULATORY THERAPEUTIC ANTIBODY TREATMENT
US20070243184A1 (en) * 2005-11-08 2007-10-18 Steven Fischkoff Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
AU2006321593B2 (en) 2005-12-07 2012-10-04 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
AU2010308030B2 (en) * 2009-10-12 2014-05-29 Pfizer Inc. Cancer treatment
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
US8778618B2 (en) 2010-04-16 2014-07-15 The Johns Hopkins University Compositions and methods for characterizing a myopathy
KR101471647B1 (ko) 2011-10-26 2014-12-11 국립암센터 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물
US20150118244A1 (en) 2012-05-10 2015-04-30 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
US10155818B2 (en) 2014-05-28 2018-12-18 Agenus Inc. Anti-GITR antibodies and methods of use thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
AU2016271591A1 (en) 2015-05-29 2017-12-21 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
JP7089470B2 (ja) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド 抗体およびその使用方法
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
CN116440257A (zh) 2017-02-28 2023-07-18 百时美施贵宝公司 具有增强的adcc的抗ctla-4抗体增强对疫苗的免疫应答的用途
EA201992755A1 (ru) 2017-05-19 2020-04-22 Уси Байолоджикс (Шанхай) Ко. Лтд. Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4)
WO2019239144A1 (en) 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna
US20210317461A1 (en) 2018-08-09 2021-10-14 Verseau Therapeutics, Inc. Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
IL287801A (en) * 2019-05-07 2022-07-01 Immunicom Inc Augmentation of responses to checkpoint inhibitors using in vitro apheresis
WO2022229644A1 (en) 2021-04-28 2022-11-03 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) * 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) * 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
JP3793693B2 (ja) 1998-12-23 2006-07-05 ファイザー インコーポレーテッド Ｃｔｌａ−４に対するヒトモノクローナル抗体
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU2001233027A1 (en) * 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
MXPA04010013A (es) 2002-04-12 2004-12-13 Medarex Inc Metodos de tratamiento utilizando anticuerpos al antigeno-4 asociado con el linfocito t citotoxico.
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
AU2006321593B2 (en) 2005-12-07 2012-10-04 E. R. Squibb & Sons, L.L.C. CTLA-4 antibody dosage escalation regimens

Also Published As

Publication number Publication date
US20040241169A1 (en) 2004-12-02
EP1639010A4 (en) 2006-08-09
EP1639010B1 (en) 2020-06-10
US7744875B2 (en) 2010-06-29
WO2005003298A3 (en) 2005-06-23
WO2005003298A2 (en) 2005-01-13
CA2527373A1 (en) 2005-01-13
US7465446B2 (en) 2008-12-16
NZ543768A (en) 2009-07-31
US20090074752A1 (en) 2009-03-19
NO20056027L (no) 2006-02-20
AU2004253865B2 (en) 2011-06-23
AU2004253865A1 (en) 2005-01-13
IL172028A (en) 2012-01-31
JP2007502330A (ja) 2007-02-08
ZA200510125B (en) 2006-12-27
NO344368B1 (no) 2019-11-18
ES2813928T3 (es) 2021-03-25
PT1639010T (pt) 2020-09-04
CY1123535T1 (el) 2022-03-24
EP1639010A2 (en) 2006-03-29
CN1816567A (zh) 2006-08-09
SI1639010T1 (sl) 2020-10-30
HUE051533T2 (hu) 2021-03-01
PL1639010T3 (pl) 2020-11-30
MXPA05012832A (es) 2006-02-13

Similar Documents

Publication Publication Date Title
DK1639010T3 (da) Terapeutisk surrogatendepunkt for anti-ctla-4-baseret immunterapi af sygdom
LTPA2018515I1 (lt) Antagonistiniai IL-17 antikūnai
CY2016035I1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
DK1802579T3 (da) Derivater af 3-arylaminopyridin
DK1587542T3 (da) Anvendelse af anti-CD100-antistoffer
DE602004026768D1 (de) Therapeutische anti-igfr1-antikörper-kombinationen
LTC1940465I2 (lt) Naujas anti-IL-1 beta antikūnų panaudojimas
ATE432056T1 (de) Zervikale zwischenwirbelprothese
DK1778618T3 (da) Syntese af triethylentetraminer
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
DK1763673T3 (da) Anvendelser af gelformuleringer
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
FR2874166B1 (fr) Agrafe chirurgicale
DK1744781T3 (da) Behandling af infektionssygdomme
DK1827483T3 (da) Terapeutiske formuleringer af keratinocyt-vækstfaktor
IS8399A (is) Form fjölgervings 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólíns
DK1833495T3 (da) Dermatologisk anvendelse af mælkeproteiner
DK1773779T3 (da) Nikotinreceptoragonister til behandling af inflammatoriske sygdomme
DK1516540T3 (da) Anvendelse af vitamin D-forbindelser
DK1812002T3 (da) Behandling af mastitis
ITVI20050007U1 (it) Pinza chirurgica di fissaggio
NO20043305D0 (no) Preparation of lodixanol
DK1687297T3 (da) Triazindimerer til behandling af autoimmunsygdomme